NO20050328L - Fremgangsmate for behandling av okklusjon av intravenost kateter ved anvendelse av fibrinolytiske metalloproteinaser - Google Patents

Fremgangsmate for behandling av okklusjon av intravenost kateter ved anvendelse av fibrinolytiske metalloproteinaser

Info

Publication number
NO20050328L
NO20050328L NO20050328A NO20050328A NO20050328L NO 20050328 L NO20050328 L NO 20050328L NO 20050328 A NO20050328 A NO 20050328A NO 20050328 A NO20050328 A NO 20050328A NO 20050328 L NO20050328 L NO 20050328L
Authority
NO
Norway
Prior art keywords
treating
intravenous catheter
catheter occlusion
fibrinolytic metalloproteinases
access device
Prior art date
Application number
NO20050328A
Other languages
English (en)
Inventor
Christopher F Toombs
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20050328L publication Critical patent/NO20050328L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04—Macromolecular materials
    • A61L29/044—Proteins; Polypeptides; Degradation products thereof
    • A61L29/048—Other specific proteins or polypeptides not covered by A61L29/045 - A61L29/047
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)

Abstract

Det tilveiebringes en fremgangsmåte for lokalisert intravaskulær tilførsel av en fibrinolytisk metalloproteinase til et menneske i mengder som både er sikre og som effektivt lyserer et okkluderende, fibrinholdig blodkoagel samtidig som de nøytraliserende virkningene av (2-makroglobulin i det sirkulerende blod unngås. Det tilveiebringes også en fremgangsmåte for behandling av et blodkoagel i, rundt eller festet til en iboende innretning for vaskulær tilgang. Videre tilveiebringes en fremgangsmåte for gjenvinning av åpenhet og funksjon av en iboende innretning for vaskulær tilgang.
NO20050328A 2002-06-21 2005-01-20 Fremgangsmate for behandling av okklusjon av intravenost kateter ved anvendelse av fibrinolytiske metalloproteinaser NO20050328L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/177,916 US7033776B2 (en) 1999-12-17 2002-06-21 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
PCT/US2003/019702 WO2004000348A1 (en) 2002-06-21 2003-06-23 Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases

Publications (1)

Publication Number Publication Date
NO20050328L true NO20050328L (no) 2005-03-17

Family

ID=29999111

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050328A NO20050328L (no) 2002-06-21 2005-01-20 Fremgangsmate for behandling av okklusjon av intravenost kateter ved anvendelse av fibrinolytiske metalloproteinaser

Country Status (17)

Country Link
US (4) US7033776B2 (no)
EP (1) EP1531856A4 (no)
JP (1) JP2005530846A (no)
KR (1) KR20050047506A (no)
CN (1) CN1674928A (no)
AU (1) AU2003279258A1 (no)
BR (1) BR0312149A (no)
CA (1) CA2489997A1 (no)
CZ (1) CZ200523A3 (no)
IL (1) IL165834A0 (no)
MX (1) MXPA04012847A (no)
NO (1) NO20050328L (no)
NZ (1) NZ537454A (no)
PL (1) PL377634A1 (no)
SK (1) SK50032005A3 (no)
WO (1) WO2004000348A1 (no)
ZA (1) ZA200500610B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9586023B2 (en) 1998-02-06 2017-03-07 Boston Scientific Limited Direct stream hydrodynamic catheter system
WO2009117663A2 (en) 2008-03-20 2009-09-24 Medrad, Inc. Direct stream hydrodynamic catheter system
US7033776B2 (en) * 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
US20080275393A1 (en) * 2004-08-24 2008-11-06 Bonnette Michael J Isolation thrombectomy catheter system
US8162878B2 (en) 2005-12-05 2012-04-24 Medrad, Inc. Exhaust-pressure-operated balloon catheter system
US20070225749A1 (en) 2006-02-03 2007-09-27 Martin Brian B Methods and devices for restoring blood flow within blocked vasculature
US8303538B2 (en) 2007-12-17 2012-11-06 Medrad, Inc. Rheolytic thrombectomy catheter with self-inflating distal balloon
US9717896B2 (en) * 2007-12-18 2017-08-01 Gearbox, Llc Treatment indications informed by a priori implant information
US20090287120A1 (en) 2007-12-18 2009-11-19 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Circulatory monitoring systems and methods
US8636670B2 (en) 2008-05-13 2014-01-28 The Invention Science Fund I, Llc Circulatory monitoring systems and methods
WO2009082669A1 (en) * 2007-12-26 2009-07-02 Medrad, Inc. Rheolytic thrombectomy catheter with self-inflating proximal balloon with drug infusion capabilities
EP2403583B1 (en) 2009-03-06 2016-10-19 Lazarus Effect, Inc. Retrieval systems
CN102791321B (zh) 2009-12-14 2017-04-05 迈克尔·G·塔尔 带有定位标记的血管内导管以及放置方法
CN107206207B (zh) * 2015-01-09 2021-04-27 阿克瑞特医学治疗有限公司 栓塞微导管
WO2016130647A1 (en) 2015-02-11 2016-08-18 Lazarus Effect, Inc. Expandable tip medical devices and methods
PL3264997T3 (pl) 2015-03-02 2019-07-31 Accurate Medical Therapeutics Ltd. Cewniki z otworami bocznymi do modyfikowania i podawania zawiesin pacjentowi
CN105561463A (zh) * 2015-12-17 2016-05-11 邓朝胜 一种Swan-Ganz漂浮导管引导鞘管导入选择性目标器官的方法
PL3451942T3 (pl) 2016-05-04 2021-07-26 Accurate Medical Therapeutics Ltd. Głowica mikrocewnika embolizacyjnego mająca wzór szczelinowy
RU2662145C2 (ru) * 2017-01-23 2018-07-23 Ильдар Наилевич Нурмеев Способ профилактики тромбоза у пациентов с центральным венозным катетером
CN107233342A (zh) * 2017-06-12 2017-10-10 揭阳市润达肠衣有限公司 一种含甲氧苄啶的固体分散体及其制备方法
KR20200085285A (ko) 2017-11-02 2020-07-14 애커러트 메디컬 테라퓨틱스 엘티디. 필터가 내장된 색전술용 카테터
US20210121675A1 (en) * 2019-10-29 2021-04-29 Bard Access Systems, Inc. Systems, Devices, and Methods For Thrombolysis
CN111141902A (zh) * 2020-01-21 2020-05-12 佘钊炜 凝血检测装置

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US81685A (en) * 1868-09-01 Improvement in harvester-rakes
FR2310133A2 (fr) * 1975-05-05 1976-12-03 Fabre Sa Pierre Nouveau medicament comportant un activateur du plasminogene perfectionne
US4447236A (en) * 1982-02-05 1984-05-08 Cordis Corporation Infusion catheter system
US4610879A (en) * 1984-01-06 1986-09-09 University Of Southern California Fibrinolytic enzyme from snake vernom
CA1237482A (en) * 1984-03-09 1988-05-31 Frank B. Stiles Catheter for effecting removal of obstructions from a biological duct
US4755167A (en) * 1984-04-10 1988-07-05 Research Corporation In vivo method for distribution and stirring of therapeutic agents
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4812405A (en) * 1986-02-18 1989-03-14 Phillips Petroleum Company Double auxotrophic mutants of Pichia pastoris and methods for preparation
US5000185A (en) * 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
ZA889415B (en) 1987-12-18 1989-09-27 Chiron Corp Compositions and method for recombinant production of crotalidus venum fibrolase
WO1990007352A1 (en) 1989-01-04 1990-07-12 Boston Scientific Corporation Angioplasty catheter
US5222941A (en) * 1990-01-12 1993-06-29 Don Michael T Anthony Method of dissolving an obstruction in a vessel
JPH05184352A (ja) 1990-01-16 1993-07-27 Centro De Ing Genetica Y Biotecnol ピヒア パストリス（Ｐｉｃｈｉａ ｐａｓｔｏｒｉｓ）酵母中での異種遺伝子の発現方法、発現ベクターおよび形質転換微生物
US5709676A (en) * 1990-02-14 1998-01-20 Alt; Eckhard Synergistic treatment of stenosed blood vessels using shock waves and dissolving medication
US5250034A (en) * 1990-09-17 1993-10-05 E-Z-Em, Inc. Pressure responsive valve catheter
US5167628A (en) * 1991-05-02 1992-12-01 Boyles Paul W Aortic balloon catheter assembly for indirect infusion of the coronary arteries
US5380273A (en) * 1992-05-19 1995-01-10 Dubrul; Will R. Vibrating catheter
EP0624642B1 (en) 1993-05-12 1999-01-20 Indian Council For Medical Research Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US5370653A (en) * 1993-07-22 1994-12-06 Micro Therapeutics, Inc. Thrombectomy method and apparatus
AU692497B2 (en) 1993-12-17 1998-06-11 Asahi Kasei Pharma Corporation Soluble thrombomodulin-containing pharmaceutical composition
FR2730579B1 (fr) 1995-02-10 1997-05-09 2B Technology Sarl Appareil portatif destine a l'exercice de diction de stimuli vocaux
GB9504657D0 (en) 1995-03-08 1995-04-26 Neil Michael J O An improved artificial airway device
US5626564A (en) * 1995-03-31 1997-05-06 Creighton University Adjustable sideholes catheter
US5830468A (en) 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
NZ505584A (en) * 1996-05-24 2002-04-26 Univ British Columbia Delivery of a therapeutic agent to the smooth muscle cells of a body passageway via an adventia
US5951981A (en) 1996-12-02 1999-09-14 Diatide, Inc. Thrombolytic agents with antithrombotic activity
US6413760B1 (en) 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
US6261820B1 (en) * 1999-10-01 2001-07-17 Amgen Inc. Fibronolytically active polypeptide
US6440414B1 (en) 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US6455269B1 (en) * 1999-12-17 2002-09-24 Amgen, Inc. Method for localized administration of fibrinolytic metalloproteinases
US7033776B2 (en) * 1999-12-17 2006-04-25 Amgen Inc. Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
AU2001281081A1 (en) * 2000-08-03 2002-02-18 Zymogenetics Inc. Disintegrin homologs, zsnk10, zsnk11, and zsnk12
US20050085769A1 (en) * 2001-07-17 2005-04-21 Kerberos Proximal Solutions Fluid exchange system for controlled and localized irrigation and aspiration
US20060095121A1 (en) * 2004-10-28 2006-05-04 Medtronic Vascular, Inc. Autologous platelet gel on a stent graft

Also Published As

Publication number Publication date
EP1531856A4 (en) 2008-08-13
US7314728B2 (en) 2008-01-01
NZ537454A (en) 2008-05-30
US20060029592A1 (en) 2006-02-09
US20060035299A1 (en) 2006-02-16
JP2005530846A (ja) 2005-10-13
BR0312149A (pt) 2005-03-29
US20020197246A1 (en) 2002-12-26
WO2004000348A1 (en) 2003-12-31
ZA200500610B (en) 2005-09-28
CN1674928A (zh) 2005-09-28
CA2489997A1 (en) 2003-12-31
US7316911B2 (en) 2008-01-08
EP1531856A1 (en) 2005-05-25
AU2003279258A1 (en) 2004-01-06
CZ200523A3 (cs) 2005-09-14
KR20050047506A (ko) 2005-05-20
PL377634A1 (pl) 2006-02-06
US7033776B2 (en) 2006-04-25
SK50032005A3 (sk) 2005-12-01
MXPA04012847A (es) 2005-02-24
IL165834A0 (en) 2006-01-15
US20080095760A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
NO20050328L (no) Fremgangsmate for behandling av okklusjon av intravenost kateter ved anvendelse av fibrinolytiske metalloproteinaser
Merport et al. Fibrin sheath stripping versus catheter exchange for the treatment of failed tunneled hemodialysis catheters: randomized clinical trial
Blättler et al. Combined regional thrombolysis and surgical thrombectomy for treatment of iliofemoral vein thrombosis
AU2003247676A1 (en) Device to create proximal stasis
EP1327454A3 (en) Method of treatment with medical agents
ATE498365T1 (de) Vorrichtung für kurzfristige behandlung von gebärmuttererkrankungen
Herrera et al. Embolization during treatment of deep venous thrombosis: incidence, importance, and prevention
Saha et al. Contemporary management of acute and chronic deep venous thrombosis.
Fiengo et al. Original approach for thrombolytic therapy in patients with Ilio-femoral deep vein thrombosis: 2 years follow-up
Beathard Complications of vascular access
NO20020326D0 (no) Fremgangsmåter for behandling og metoder for medikament screening
DE60021111D1 (de) Verwendung von fibrinolytischen metallproteinasen zur behandlung von blutgerinseln
DK1222854T3 (da) Forebyggelse og behandling af sygdomme forbundet med blodkoagulering
Anesäter et al. The influence on wound contraction and fluid evacuation of a rigid disc inserted to protect exposed organs during negative pressure wound therapy
Bauersachs et al. Overview of current evidence on the impact of the initial high dose of the direct factor Xa inhibitor rivaroxaban on thrombus resolution in the treatment of venous thromboembolism
Chaudhry et al. Prevention of venous thromboembolism in patients with hemorrhagic stroke
RS20050031A (en) Method for treatment of indwelling catheter occlusion using fibrinolytic metalloproteinases
Peden et al. The case for thrombolysis for iliofemoral venous thrombosis
Sciolaro et al. Thrombectomy and isolated limb perfusion with urokinase in the treatment of phlegmasia cerulea dolens
Molinari et al. The activity of rtcu-PA generated from rscu-PA during lysis of plasma clots in vitro is not affected by the heparin-dependent u-PA inhibitors
Hoch Venous Etiologies of Acute Limb Ischemia
RU2222264C2 (ru) Способ лечения трофических язв венозной этиологии
Alkhateep et al. Clinical and radiological outcomes of adjuvant catheter-directed thrombolysis of acute iliofemoral venous thrombosis compared to standard anticoagulant therapy: a randomized controlled study
Hiemeyer The fibrinolytic activity of blood derived from vessel wall
Wittens et al. Management of iliofemoral DVT

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application